| Literature DB >> 24738060 |
M Lanciotti1, L Masieri1, M R Raspollini2, A Minervini1, A Mari1, G Comito3, E Giannoni3, M Carini1, P Chiarugi3, S Serni1.
Abstract
INTRODUCTION: The aim of our work was to investigate the causal connection between M1 and M2 macrophage phenotypes occurrence and prostate cancer, their correlation with tumor extension (ECE), and biochemical recurrence (BR). PATIENT AND METHODS: Clinical and pathological data were prospectively gathered from 93 patients treated with radical prostatectomy. Correlations of commonly used variables were evaluated with uni- and multivariate analysis. The relationship between M1 and M2 occurrence and BR was also assessed with Kaplan-Meier survival analysis.Entities:
Mesh:
Year: 2014 PMID: 24738060 PMCID: PMC3967497 DOI: 10.1155/2014/486798
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Presence of both M1 and M2 that were characterized by a red cytoplasm due to chromogen FAST RED for CD68 (M1) or with a brown cytoplasm due to chromogen diaminobenzidine (DAB) for CD163 (M2).
Clinical presentation, pathologic findings, and follow-up of the 93 patients.
| Macrophages population | Total of patients | M1 | M2 |
|---|---|---|---|
|
| 93 | 34 (36.6) | 59 (63.4) |
| Count in three hot spots | Mean (median) | 12.06 (6) | 17.18 (10) |
| Density of macrophages M1 and M2 in three hot spots according to median number |
43 below median number | ||
|
| |||
| Preoperative variables | |||
| Age (yy) median (IQR) | 67 (45–75) | 64 (55–74) | 67 (45–75) |
| Total PSA (ng/mL) median (IQR) | 7.6 (1.0–86.8) | 8.3 (2.5–47.7) | 7.0 (1–76.8) |
| Biopsy Gleason score | |||
| 6 | 50 (53.8) | 19 (55.9) | 31 (52.6) |
| 7 | 28 (30.1) | 12 (35.3) | 16 (27.1) |
| 8–10 | 15 (16.1) | 3 (8.8) | 12 (20.3) |
|
| |||
| Postoperative variables | |||
| Organ confine disease (OC) | 33 (35.5) | 19 (55.9) | 14 (23.8) |
| Extracapsular extension (ECE) | 60 (64.5) | 15 (44.1) | 45 (76.2) |
| TNM stage | |||
| T2 | 33 (35.5) | 19 (55.9) | 14 (23.8) |
| T3a | 35 (37.6) | 7 (20.6) | 28 (47.4) |
| T3b | 23 (24.8) | 8 (23.5) | 15 (25.4) |
| T4 | 2 (2.1) | 0 | 2 (3.4) |
| Pathologic Gleason score | |||
| 6 | 30 (32.2) | 13 (38.2) | 17 (28.8) |
| 7 | 40 (43) | 16 (47.1) | 24 (40.7) |
| 8–10 | 23 (24.8) | 5 (14.7) | 18 (30.5) |
| Lymph node involvement | 5 (5.3) | 2 (5.9) | 3 (5.1) |
| Positive surgical margin | 11 (11.8) | 2 (5.9) | 9 (15.2) |
| Follow-up (months) mean (SD) | 50.4 (19.2) | 55.5 (21.2) | 47.6 (16.3) |
| Biochemical recurrence | 23 (24.7) | 7 (20.6) | 16 (27.1) |
Univariate (Pearson χ 2 test, t-test, and Mann Whitney test) and multivariate (logistic regression) analysis of common variables to predict extracapsular extension (ECE) of PCa.
| Variables |
Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
|
| Risk ratio | 95% CI | ||
| Preoperative PSA | Ns | Not included in analysis | ||
| Biopsy GS > 7 |
| 0.07 | 4.21 | 1.10–19.62 |
| Anatomopathological GS > 7 |
|
| 10.65 | 1.11–102.26 |
| Lymphnode invasion | Ns | Not included in analysis | ||
| M1/M2 |
|
|
|
|
Univariate (Pearson χ 2 test, Mann Whitney Test, and t-test) and multivariate (Cox proportional hazard model) analysis of common variables to predict BCR.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
|
| Risk ratio | 95% CI | ||
| Preoperative PSA | Ns | — | ||
| Biopsy GS > 7 |
| 0.07 | 2.26 | 1.1–10.47 |
| Anatomopathological GS > 7 |
|
|
|
|
| Pathological stage |
|
|
|
|
| Lymphnode invasion | Ns | — | ||
| Status | Ns | — | ||
| Surgical margin status | Ns | — | ||
| High density of macrophages M1 and M2 in three hot spots (above median value) |
| 0.09 | 2.53 | 1.6–9.67 |
| M1-2 phenotype | Ns | — | ||
Figure 2Biochemical recurrence (BCR) free survival curves at the Kaplan-Meier analysis of our 93 patients study population based on median number of macrophages. The blue line represents BCR free survival curve of patients with low density of macrophages M1 and M2 in three hot spots (n° of macrophages < median number), while the red line represents those with high density of M1 and M2 in three hot spots (>median number). BCR free survival rates at 36 and 60 months were 94.4 versus 74.0 and 85.1 versus 62.2, respectively, P = 0.05.
Figure 3Biochemical recurrence (BCR) free survival curves at the Kaplan-Meier analysis of our 93 patients study population stratified for M1 and M2 macrophages prevalence. The blue line represents BCR free survival curve of patients with M1 macrophage prevalence, while the red line represents those with M2 macrophage prevalence. BCR free survival rates at 36 and 60 months were 94.1 versus 78.2 and 77.4 versus 71.0, respectively.